The introduction of the tyrosine kinase inhibitor imatinib mesylate (Gleevec) has profoundly changed the treatment paradigm for patients with chronic myelogenous leukemia (CML).
Marcel Devetten, MD
Advertisement
Articles by Marcel Devetten, MD
Advertisement
Latest Updated Articles
- Refractory CML: Not All Forms of Resistance Are Equal
Published: April 15th 2008 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
AI-Powered Scout Platform Could Enhance Oncology Decision-Making With Data- and Expert-Driven Insights
2
FDA Grants Interchangeability Designation to 2 Denosumab Biosimilars
3
Sac-TMT Combo Produces Encouraging Activity in Pretreated Metastatic CRPC
4
Molecular Insights Into Cancer Cachexia: An Evolution in Identifying the Syndrome
5
